TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30914073

Group type: EXPERIMENTAL
Intervention: BD+50 mg EEO/kg
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: BD+100 mg EEO/kg
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: BD+150 mg OEO/kg
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: BD+300 mg OEO/kg
Number of subjects: 800

Group type: COMPARATOR
Intervention: BD (control)
Number of subjects: 800
Study: 29044707

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU, two doses at baseline and 8 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (matching placebo at baseline and 8 weeks)
Number of subjects: 120
Study: 26998954

Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg intravenously
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg orally
Number of subjects: 16
Study: 24667664

Group type: EXPERIMENTAL
Intervention: Intensive nursing care with electronic followup system
Number of subjects: 840
Study: 21940922

Group type: EXPERIMENTAL
Intervention: Specialist-taught PE (90 minutes per week from visiting specialists)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Common-practice PE (150 minutes per week from generalist classroom teachers)
Number of subjects: 620
Study: 21395144

Group type: EXPERIMENTAL
Intervention: Selective endotoxin hemoperfusion with Polymyxin B and Alteco LPS adsorber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17272337

Group type: EXPERIMENTAL
Intervention: Biphasic shocks (50, 100, 150, up to 175 J)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Monophasic shocks (100, 200, 300, up to 360 J)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Biphasic shocks
Number of subjects: 154

Group type: COMPARATOR
Intervention: Monophasic shocks
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 16234460

Group type: EXPERIMENTAL
Intervention: 3D animations and surgical videos (n=90)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Surgical videos only (n=82)
Number of subjects: 172
Study: 11820865

Group type: EXPERIMENTAL
Intervention: TMZ 10 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TMZ 20 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TMZ 40 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: TMZ 80 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 10424325

Group type: EXPERIMENTAL
Intervention: Atovaquone alone (1000 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Atovaquone with proguanil (1000 mg + 400 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Proguanil alone (400 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Proguanil with atovaquone (400 mg + 1000 mg)
Number of subjects: 18
Study: 7802104

Group type: EXPERIMENTAL
Intervention: Low-dose amisulpride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2104072

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenously rapidly over 2‐4 s (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam intravenously over 1‐2 min, mean dose 15.9 mg (Group B)
Number of subjects: 100
Study: 477025

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31934844

Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation (MMR) programme
Number of subjects: 603

Group type: COMPARATOR
Intervention: Ordinary care and treatment in primary care (reference group)
Number of subjects: 603
Study: 30803472

Group type: EXPERIMENTAL
Intervention: Electric toothbrush
Number of subjects: 120

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 120
Study: 28244124

Group type: EXPERIMENTAL
Intervention: Early endoscopy and possible treatment escalation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study: 25548839

Group type: EXPERIMENTAL
Intervention: Xeomin (XEO)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dysport (DYS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both Xeomin and Dysport
Number of subjects: 80
Study: 24201169

Group type: EXPERIMENTAL
Intervention: Transdermal continuous oxygen therapy (TCOT) for 4 weeks as an adjunct to standard care.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard care alone (control group).
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Transdermal continuous oxygen therapy (TCOT).
Number of subjects: 17
Study: 21867492

Group type: EXPERIMENTAL
Intervention: Mailed educational reminder (FOBT plus a mailed reminder)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Usual care (FOBT alone)
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Mailed educational reminder
Number of subjects: 769
Study: 19286091

Group type: EXPERIMENTAL
Intervention: SCH 530348 10 mg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: SCH 530348 20 mg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: SCH 530348 40 mg
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: SCH 530348 0.5 mg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: SCH 530348 1.0 mg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: SCH 530348 2.5 mg
Number of subjects: 1030
Study: 17398194

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 1873

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study: 15033841

Group type: EXPERIMENTAL
Intervention: Helmet + educational pack
Number of subjects: 1213

Group type: EXPERIMENTAL
Intervention: Helmet + multifaceted intervention
Number of subjects: 1213
Study: 18007128

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment tools for classification
Number of subjects: 0
Study: 10823375

Group type: EXPERIMENTAL
Intervention: Microparticle enzyme immunoassay (MEIA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: High-performance liquid chromatography-mass spectrometry (HPLC-MS)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Time after transplantation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Hemoglobin concentration
Number of subjects: 74
Study: 8722747

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives
Number of subjects: 41837

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives with onset at or before age 45
Number of subjects: 41837

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer in first-degree relatives with onset after age 45
Number of subjects: 41837

Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer in first-degree relatives
Number of subjects: 41837
Study: 1818543

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA) (n = 25)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) (n = 27)
Number of subjects: 52
Study: 7059325

Group type: EXPERIMENTAL
Intervention: Chinese Air Force (CAF) protocol with a constant speed of 3.5 mph and a 5% increase in elevation every 3 min
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Balke protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: All five protocols
Number of subjects: 24
Study: 29903473

Group type: EXPERIMENTAL
Intervention: Experimental Formula 1 (EF1; 43% of total palmitate at sn‐2; n = 166)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Experimental Formula 2 (EF2; 51% of total palmitate at sn‐2; n = 160)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Control Formula (CF; 16% of total palmitate at sn‐2; n = 162)
Number of subjects: 488
Study: 29215191

Group type: EXPERIMENTAL
Intervention: Team‐Game Tournament
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Jigsaw
Number of subjects: 52
Study: 26542420

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 97
Study: 24884894

Group type: EXPERIMENTAL
Intervention: Impaired fasting blood glucose
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Raised fasting blood glucose or currently on medication for diabetes
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in men
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in women
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in rural areas
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in urban areas
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in males in rural areas
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Diabetes prevalence in males in urban areas
Number of subjects: 3056

Group type: EXPERIMENTAL
Intervention: Comparison to previous estimates
Number of subjects: 3056
Study: 22415888

Group type: EXPERIMENTAL
Intervention: Aliskiren 300mg plus Losartan 100mg daily for 36 weeks
Number of subjects: 465

Group type: COMPARATOR
Intervention: Losartan 100mg daily for 36 weeks
Number of subjects: 465
Study: 19855266

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (30 at-risk subjects)
Number of subjects: 70
Study: 18049253

Group type: EXPERIMENTAL
Intervention: Technique 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technique 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Technique 3
Number of subjects: 0
Study: 16318744

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 36
Study: 12097848

Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at a dose of 1.2 ml
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at a dose of 2.4 ml
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SonoVue (BR1) at doses of 0.3, 0.6, 1.2, and 2.4 ml
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: SonoVue (BR1)
Number of subjects: 113
Study: 9922304

Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: H. pylori presence
Number of subjects: 120
Study: 7586113

Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms.kg‐1 and succinylcholine 1.5 mg.kg‐1 (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Succinylcholine 1.5 mg.kg‐1 alone (n = 21)
Number of subjects: 41
Study: 2275907

Group type: COMPARATOR
Intervention: 3% 2‐chloroprocaine (C)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 1.5% lidocaine (L)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 1.5% mepivacaine (M)
Number of subjects: 84
Study: 30416189

Group type: EXPERIMENTAL
Intervention: Statin group (n=81)
Number of subjects: 414

Group type: COMPARATOR
Intervention: No statin group (n=333)
Number of subjects: 414
Study: 29901598

Group type: EXPERIMENTAL
Intervention: Interscalene block using ropivacaine 0.25% 10 mL including dexamethasone 5 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no interscalene block)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (postoperative pulmonary function tests)
Number of subjects: 44
Study: 26749187

Group type: EXPERIMENTAL
Intervention: 90° counterclockwise rotation (CCR) of the endotracheal tube (ETT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard bevel direction (facing left)
Number of subjects: 60
Study: 24768112

Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg orally twice daily)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 417
Study: 22325115

Group type: EXPERIMENTAL
Intervention: Intracervical 2% lidocaine gel
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 20455705

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (12 mg for women, 15 mg for men) for 18 months
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo for 18 months
Number of subjects: 231
Study: 17039265

Group type: EXPERIMENTAL
Intervention: Sequential doxorubicin 75 mg/M2 q2 wks x 3 and docetaxel 40 mg/M2 weekly x 6
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gene expression in IBC
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Oncotype DX Recurrence Score
Number of subjects: 70
Study: 15752394

Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg kg(‐1))
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg kg(‐1))
Number of subjects: 66

Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg kg(‐1))
Number of subjects: 66
Study: 12045510

Group type: EXPERIMENTAL
Intervention: Neuroreflexotherapy intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard protocol (Control)
Number of subjects: 104
Study: 9447860

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 8535577

Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 0
Study: 2146060

Group type: EXPERIMENTAL
Intervention: Isradipine (twice a day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (twice a day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isradipine (once a day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (once a day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (once a day)
Number of subjects: 100
Study: 509955

Group type: EXPERIMENTAL
Intervention: GravigardR (commercially available Cu-7-IUD)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Cu-7-Nullip (small-sized Cu-7-IUD for nulliparous women)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Both GravigardR and Cu-7-Nullip
Number of subjects: 516
Study: 31840400

Group type: EXPERIMENTAL
Intervention: Internalized stigma scale for PLHIV
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Healthcare settings stigma measure for PLHIV
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Fear and judgement scale for community members
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Perceived stigma in the community scale for community members
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Perceived stigma in healthcare settings scale for community members
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Fear and judgement scale for health workers
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Perceived stigma in the community scale for health workers
Number of subjects: 11395

Group type: EXPERIMENTAL
Intervention: Perceived co-worker stigma in healthcare settings scale for health workers
Number of subjects: 11395
Study: 27989952

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 0
Study: 25331853

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle interventions (diet and exercise recommendations)
Number of subjects: 2186
Study: 23635771

Group type: EXPERIMENTAL
Intervention: 30 hours of sleep deprivation with psychological stress
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no sleep deprivation)
Number of subjects: 23
Study: 21372740

Group type: EXPERIMENTAL
Intervention: CD133 cells from bone marrow (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CD133 cells from peripheral blood (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Drug therapy alone (group C)
Number of subjects: 15
Study: 18241712

Group type: EXPERIMENTAL
Intervention: Submucosal temperature‐controlled radiofrequency tissue volume reduction (TCRFTVR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resection with microdebrider (SMRM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both TCRFTVR and SMRM
Number of subjects: 30
Study: 15960567

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12001178

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paroxetine (in subgroup analysis)
Number of subjects: 24
Study: 10497445

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (sIT) applied in 29 patients with pollinosis and 27 patients sensitive to house dust mite.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine pharmacotherapy alone (control group).
Number of subjects: 112

Group type: COMPARATOR
Intervention: Laboratory workers with no history of atopy (control group).
Number of subjects: 112
Study: 7481173

Group type: EXPERIMENTAL
Intervention: Group-living (GL-group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (C-group)
Number of subjects: 108
Study: 1673097

Group type: COMPARATOR
Intervention: Fenoldopam with food
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoldopam fasting
Number of subjects: 18
Study: 7457560

Group type: EXPERIMENTAL
Intervention: Algorithm format teaching aid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Prose form teaching aid
Number of subjects: 29
Study: 31744319

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28975711

Group type: EXPERIMENTAL
Intervention: Temporal brow lift (TBL)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Internal browpexy (IBP)
Number of subjects: 32
Study: 28655559

Group type: EXPERIMENTAL
Intervention: Gym-based exercise program for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home-based exercise program for 12 months with telephone follow-up for the first 10 weeks
Number of subjects: 0
Study: 26631095

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate 40 mg twice weekly with daily oral estrogen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo twice weekly with daily oral estrogen
Number of subjects: 70
Study: 24548394

Group type: COMPARATOR
Intervention: Progynova only (Group A)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Progynova plus Femoston (Group B)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Progynova only (2011 comparison)
Number of subjects: 1072
Study: 20886631

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil or equivalent agents
Number of subjects: 35853
Study: 19041049

Group type: EXPERIMENTAL
Intervention: Dofetilide (class III antiarrhythmic drug)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study: 16609032

Group type: EXPERIMENTAL
Intervention: l-selenomethionine (SeMet)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 66
Study: 14724129

Group type: EXPERIMENTAL
Intervention: Chest pain observation unit
Number of subjects: 972

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 972
Study: 11535875

Group type: EXPERIMENTAL
Intervention: Aspirin (160 or 300 mg/day)
Number of subjects: 274
Study: 9249636

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 14
Study: 8213442

Group type: EXPERIMENTAL
Intervention: Teboroxime scanning
Number of subjects: 35

Group type: COMPARATOR
Intervention: Redistribution imaging (thallium)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Teboroxime imaging
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thallium reinjection scanning
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thallium reinjection
Number of subjects: 35
Study: 3323604

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA) + Heparin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nifedipine therapy
Number of subjects: 2
Study: 30053863

Group type: EXPERIMENTAL
Intervention: No prior knowledge of blood pressure
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Urinalysis test
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Glycosuria
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Primary healthcare sources
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Use of herbal mixtures
Number of subjects: 145
Study: 25863520

Group type: EXPERIMENTAL
Intervention: Brief mindfulness practice (Brief‐MP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (sham meditation)
Number of subjects: 44
Study: 24598496

Group type: EXPERIMENTAL
Intervention: Irrigation with 2.5% sodium hypochlorite (NaOCl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Irrigation with 2% chlorhexidine (CHX)
Number of subjects: 80
Study: 22796948

Group type: EXPERIMENTAL
Intervention: Liquid meal replacers (MR, 190 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yogurt (190 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bagel with cream cheese and juice (400 kcal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hamburger with bun and soft drink (400 kcal)
Number of subjects: 0
Study: 20399951

Group type: EXPERIMENTAL
Intervention: Advanced supply of emergency contraception (EC) pills with unlimited supply thereafter upon request
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine postpartum contraceptive care (RCA)
Number of subjects: 50
Study: 18599890

Group type: EXPERIMENTAL
Intervention: Taxus stent
Number of subjects: 1700

Group type: COMPARATOR
Intervention: CoStar stent
Number of subjects: 1700
Study: 16162987

Group type: EXPERIMENTAL
Intervention: Functional knee brace
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no bracing)
Number of subjects: 42